Meeting
2019 ASCO Annual Meeting
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
Authors
Matthew H. Taylor
Oregon Health & Science University, Portland, OR
Matthew H. Taylor , Justin F. Gainor , Mimi I-Nan Hu , Viola Weijia Zhu , Gilberto Lopes , Sophie Leboulleux , Marcia S. Brose , Martin H. Schuler , Daniel W. Bowles , Dong-Wan Kim , Christina S Baik , Elena Garralda , Chia-Chi Lin , Douglas Adkins , Debashis Sarker , Giuseppe Curigliano , Hui Zhang , Corinne Clifford , Christopher D. Turner , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT03037385
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6018)
DOI
10.1200/JCO.2019.37.15_suppl.6018
Abstract #
6018
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
First Author: Aaron Scott Mansfield
Poster
2021 ASCO Annual Meeting
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
First Author: Vivek Subbiah
Poster
2020 ASCO Virtual Scientific Program
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
First Author: Justin F. Gainor
Poster
2020 ASCO Virtual Scientific Program
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
First Author: Manisha H. Shah